S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

$14.56
+0.09 (+0.62%)
(As of 03/18/2024 ET)
Today's Range
$14.54
$14.61
50-Day Range
$13.92
$15.04
52-Week Range
$13.19
$17.15
Volume
1.21 million shs
Average Volume
1.86 million shs
Market Capitalization
$46.08 billion
P/E Ratio
22.06
Dividend Yield
3.57%
Price Target
$22.00

Takeda Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
51.1% Upside
$22.00 Price Target
Short Interest
Healthy
0.20% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.73mentions of Takeda Pharmaceutical in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$30 M Sold Last Quarter
Proj. Earnings Growth
-37.09%
From $1.51 to $0.95 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Medical Sector

147th out of 947 stocks

Pharmaceutical Preparations Industry

60th out of 435 stocks

TAK stock logo

About Takeda Pharmaceutical Stock (NYSE:TAK)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Stock Price History

TAK Stock News Headlines

Like Tiny Crypto Retirement Funds
The crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds.
Takeda staying in Kendall Square
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Championing Rare Voices on Rare Disease Day
5 Best Japanese Stocks To Buy In 2024
Q4 2023 Halozyme Therapeutics Inc Earnings Call
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
3/18/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/09/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
49,095
Year Founded
1781

Price Target and Rating

Average Stock Price Target
$22.00
High Stock Price Target
$30.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+50.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$2.35 billion
Pretax Margin
3.72%

Debt

Sales & Book Value

Annual Sales
$29.81 billion
Cash Flow
$3.65 per share
Book Value
$14.86 per share

Miscellaneous

Outstanding Shares
3,164,800,000
Free Float
3,163,534,000
Market Cap
$46.14 billion
Optionable
Optionable
Beta
0.54

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Christophe Weber (Age 58)
    President, CEO & Representative Director
    Comp: $3.84M
  • Mr. Constantine Saroukos (Age 53)
    CFO & Representative Director
    Comp: $2.39M
  • Dr. Andrew S. Plump (Age 59)
    President of Research & Development and Representative Director
    Comp: $2.74M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 67)
    Member of Management Board
  • Mr. Salvatore Alesci M.D. (Age 49)
    Ph.D., Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller
  • Mr. Iwaaki Taniguchi
    Senior Vice President of Corporate Finance & Controlling Department
  • Mr. Gabriele Ricci (Age 46)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Finance

Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Takeda Pharmaceutical was last updated on Friday, March 15, 2024 at 3:33 AM.

Pros

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • Takeda Pharmaceutical has a diverse portfolio of pharmaceutical products in areas such as gastroenterology, rare diseases, oncology, and neuroscience, providing revenue stability and growth potential.
  • The company has engaged in numerous collaborations and licensing agreements with various biotech and pharmaceutical companies, enhancing its research and development capabilities and potentially leading to innovative product offerings.
  • Recent financial disclosures show that Takeda Pharmaceutical has a market capitalization of $46.11 billion, indicating a strong presence in the market and potential for further growth.
  • Takeda Pharmaceutical's stock price has shown resilience with a one year high of $17.15, suggesting positive investor sentiment and potential for capital appreciation.
  • The company's debt-to-equity ratio of 0.64, current ratio of 1.06, and quick ratio of 0.55 indicate a healthy financial position and efficient management of resources.

Cons

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Takeda Pharmaceutical's product development and market access.
  • Despite collaborations and licensing agreements, there is inherent risk in research and development, with no guarantee of successful product launches or market acceptance.
  • The company's PEG ratio of 3.28 and beta of 0.54 suggest potential overvaluation and sensitivity to market fluctuations, posing risks to investor returns.
  • Takeda Pharmaceutical's one year low of $13.19 indicates volatility in stock performance, highlighting potential downside risks for investors.
  • Hedge funds and institutional investors owning 2.65% of the company's stock may lead to market influence that could impact stock price movements and investor sentiment.

TAK Stock Analysis - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for Takeda Pharmaceutical's stock. Their TAK share price targets range from $14.00 to $30.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 51.1% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2024?

Takeda Pharmaceutical's stock was trading at $14.27 on January 1st, 2024. Since then, TAK shares have increased by 2.0% and is now trading at $14.56.
View the best growth stocks for 2024 here
.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a decrease in short interest in February. As of February 29th, there was short interest totaling 6,260,000 shares, a decrease of 21.7% from the February 14th total of 7,990,000 shares. Based on an average daily volume of 1,880,000 shares, the short-interest ratio is currently 3.3 days. Approximately 0.2% of the company's stock are sold short.
View Takeda Pharmaceutical's Short Interest
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TAK earnings forecast
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) released its quarterly earnings data on Thursday, February, 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The company had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a trailing twelve-month return on equity of 12.57%.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.52 per share and currently has a dividend yield of 3.64%. The dividend payout ratio is 78.79%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, TAK will have a dividend payout ratio of 54.74% next year. This indicates that the company will be able to sustain or increase its dividend.

What ETFs hold Takeda Pharmaceutical's stock?
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2023 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of 3.030-3.030 for the period. The company issued revenue guidance of $26.9 billion-$26.9 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (0.45%), Goldman Sachs Group Inc. (0.14%), Goldman Sachs Group Inc. (0.14%), Brandes Investment Partners LP (0.08%), Northern Trust Corp (0.06%) and Managed Asset Portfolios LLC (0.06%).
View institutional ownership trends
.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
This page (NYSE:TAK) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners